Full-Time

Senior/Principal Scientist

Cellular Neuroscience

Confirmed live in the last 24 hours

Calico Labs

Calico Labs

201-500 employees

Research and develop treatments for aging

Compensation Overview

$166k - $207kAnnually

+ Annual Cash Bonuses

Senior

San Bruno, CA, USA

Must be willing to work onsite 5 days a week.

Category
Public Health
Biology Lab & Research
Biology & Biotech
Required Skills
Data Analysis
Requirements
  • PhD in Neuroscience, Cell Biology, or a related field, and at least 5+ years post-PhD experience in academia or industry, with demonstrated experience in *in vitro* modeling of neurodegenerative, neuroimmune or age-related diseases
  • Proven expertise in cutting edge techniques in cell biology including microscopy, real-time analysis, organelle biology, histology, image analysis, etc.
  • Strong interest in translational research, especially pertaining to neurological diseases, with a proven track record in at least one prominent area of cell biology
  • Strong data analysis and interpretation skills
  • Excellent communication and interpersonal skills, with the ability to work effectively in a team-oriented environment
  • Must be willing to work onsite 5 days a week
Responsibilities
  • Design, develop, and characterize innovative *in vitro* models of neurodegeneration and aging, incorporating findings from human cohorts
  • Conduct cell biological investigation to validate targets, explore novel mechanisms of action (MoA) for drug candidates, and test causal hypotheses generated from internal discovery efforts
  • Perform a range of techniques, including microscopy, biochemistry, histology and real-time and/or high-throughput imaging
  • Independently generate testable disease hypotheses, conduct experiments, analyze and interpret data, prepare reports, and effectively communicate findings
  • Maintain accurate records of experimental data/protocols per Calico guidelines
  • Contribute to a collaborative and multidisciplinary team environment, working closely with scientists across various disciplines to advance translational programs

Calico Labs focuses on researching the biology of aging and creating treatments for diseases related to aging. The company uses advanced technologies to explore how aging works and what can be done to combat age-related illnesses. By collaborating with academic institutions and other biopharmaceutical companies, Calico Labs enhances its research efforts and aims to turn scientific findings into real medical solutions. This partnership model allows for shared knowledge and resources, which can lead to faster and more impactful discoveries. Unlike many competitors, Calico Labs emphasizes a culture of curiosity and interdisciplinary teamwork, which helps drive innovation in the field of aging. The ultimate goal of Calico Labs is to significantly improve the understanding of aging and develop effective treatments for age-related diseases.

Company Size

201-500

Company Stage

Seed

Total Funding

$2M

Headquarters

South San Francisco, California

Founded

2013

Simplify Jobs

Simplify's Take

What believers are saying

  • Calico's drug fosigotifator is in the FDA's START Pilot Program, accelerating development.
  • The company benefits from Google's $1.5B investment, boosting financial stability.
  • Calico's AI-driven drug discovery approach aligns with industry trends, enhancing innovation.

What critics are saying

  • Over-reliance on AbbVie partnership could pose risks if strategic misalignments occur.
  • Focus on rare diseases like VWM may limit market size and revenue potential.
  • Intensifying competition in anti-aging research could dilute Calico's market influence.

What makes Calico Labs unique

  • Calico Labs focuses on aging and age-related diseases, a niche in biopharmaceuticals.
  • The company leverages strategic partnerships, enhancing research and development capabilities.
  • Calico's collaboration with Broad Institute targets age-related neurodegeneration, extending until 2029.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Performance Bonus

Professional Development Budget

Company News

PR Newswire
Jun 7th, 2024
Calico Life Sciences Announces That Fosigotifator (Abbv-Cls-7262) For Vanishing White Matter Disease Has Been Selected For The Fda Start Pilot Program

SOUTH SAN FRANCISCO, Calif., June 7, 2024 /PRNewswire/ -- Calico Life Sciences LLC (Calico), a biotechnology organization focused on the biology of aging and age-related diseases, and founded by Alphabet and Arthur D. Levinson, Ph.D., today announced that its investigational eIF2B activator fosigotifator (ABBV-CLS-7262) has been accepted into the U.S. Food and Drug Administration (FDA) Support for clinical Trials Advancing Rare disease Therapeutics (START) Pilot Program. Fosigotifator is being developed by Calico and AbbVie pursuant to their 2014 collaboration as a potential treatment for Vanishing White Matter (VWM) disease.FDA's Center for Biologics Evaluation and Research (CBER) and Center for Drug Evaluation and Research (CDER) initiated the START Pilot Program to help further accelerate the development of novel drug and biological products for rare diseases. Selected participants will be able to obtain frequent advice and enhanced communication with FDA review staff to address program-specific development issues, including, but not limited, to clinical study design, choice of control group, and fine-tuning the choice of patient population."Calico is honored that fosigotifator has been selected by CDER as one of three candidates for the FDA's innovative START Pilot Program. The inclusion of fosigotifator underscores the potential of this investigational therapy in addressing the unmet needs of individuals and families affected by Vanishing White Matter Disease," said Arthur D

PR Newswire
May 9th, 2024
Calico And Broad Institute Extend Collaboration Adding Focus On Age-Related Neurodegeneration

SOUTH SAN FRANCISCO, Calif. and CAMBRIDGE, Mass., May 9, 2024 /PRNewswire/ -- Calico Life Sciences LLC (Calico) and the Broad Institute of MIT and Harvard, announced today that the two organizations have further extended their partnership with an added focus on age-related neurodegeneration. Initially announced in March 2015, this renewed agreement extends the collaboration until September 2029 and will continue to support ongoing programs focused on the biology and genetics of aging as well as early-stage drug discovery. Terms of the agreement were not disclosed."We are pleased to continue our collaboration with the Broad Institute. It is entering its tenth year and we've made a considerable amount of progress, including discoveries that could make immunotherapies more effective for more patients. We are currently testing this approach in two early-stage clinical trials evaluating a pair of PTPN2 inhibitors," said Arthur D

PR Newswire
Mar 28th, 2024
Calico Appoints Michael Lenardo, M.D., As Chief Scientific Officer

SOUTH SAN FRANCISCO, Calif., March 28, 2024 /PRNewswire/ -- Calico Life Sciences LLC (Calico), a biotechnology organization focused on the biology of aging and age-related diseases, and founded by Alphabet and Arthur D. Levinson, Ph.D., today announced the appointment of Michael Lenardo, M.D., as its new Chief Scientific Officer. Dr. Lenardo will join the company in August after completing his term as Co-Director of the National Institute of Allergy and Infectious Diseases (NIAID) Clinical Genomics Program at the National Institutes of Health.Dr. Lenardo is an accomplished molecular immunologist and geneticist whose medical research career spans four decades. He has been recognized for his work on fundamental immunological mechanisms and is particularly known for discovering the genetic basis, pathogenesis, and treatment of several congenital disorders of the immune system."Securing someone of Mike's caliber for the critical role of Chief Scientific Officer is a major achievement for Calico," said Dr

CaliCo Labs
Dec 6th, 2023
Calico Appoints Jessica Wilan as Head of Human Resources

Calico appoints Jessica Wilan as Head of Human Resources.

PR Newswire
Oct 4th, 2023
Nature Publishes Discovery And Preclinical Results For Abbv-Cls-484, A Potential First-In-Class Ptpn2/N1 Inhibitor In Cancer Immunotherapy

NORTH CHICAGO, Ill. and SOUTH SAN FRANCISCO, Calif., Oct. 4, 2023 /PRNewswire/ -- AbbVie (NYSE: ABBV), the Broad Institute of MIT and Harvard, and Calico Life Sciences today announced the publication in Nature of the discovery and preclinical data that demonstrate investigational ABBV-CLS-484 is a potential first-in-class, orally bioavailable, PTPN2/N1 phosphatase inhibitor that enhances anti-tumor immunity. The findings, based on research conducted by AbbVie in collaboration with the Broad Institute and Calico, support the development of ABBV-CLS-484 as a promising new strategy for cancer immunotherapy.Titled "The PTPN2/PTPN1 inhibitor ABBV-CLS-484 unleashes potent anti-tumour immunity," the paper highlights the novel structural insights and design that led to the discovery of ABBV-CLS-484 and its dual mechanism of action that targets tumor cells and suppresses their growth, as well as promotes the activation of several immune cell types to increase their anti-tumor activity.1Researchers at the Broad previously identified protein tyrosine phosphatase non-receptor type 2 (PTPN2) and its closely related paralog PTPN1 as potential targets for cancer immunotherapy through an in vivo CRISPR screen.2 However, this challenging target class had previously been deemed "undruggable". AbbVie researchers overcame the challenges and discovered the dual PTPN2/N1 inhibitor, ABBV-CLS-484, through structure-based drug design and optimization of drug-like properties.Discovery scientists at AbbVie, the Broad, and Calico further uncovered the biology and mechanism of action of ABBV-CLS-484. Preclinical findings presented demonstrate that ABBV-CLS-484 treatment amplifies the tumor intrinsic response to interferon and increases the activation and function of several immune cell subsets promoting cellular pathways including JAK-STAT signaling in animal models